Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer

Gastric Cancer

Volumn 18, Issue 4, 2015, Pages 711-719

  Saito, Takuya ^a   Nakanishi, Hayao ^b   Mochizuki, Yoshinari ^c   Ito, Seiji ^b   Ito, Yuichi ^b   Misawa, Kazunari ^b   Yatabe, Yasushi ^b   Yamamichi, Keigo ^d   Kondo, Eisaku ^a,b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Department of Surgery   (Japan)

^d Osaka Saiseikai Izuo Hospital   (Japan)

Author keywords

EGFR; Gastric cancer; HER2; Immunohistochemistry; Liver metastases; Molecular targeting therapy; Peritoneal metastases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; COMPARATIVE STUDY; DISTANT METASTASIS; FEMALE; GENE OVEREXPRESSION; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH BIOPSY; STOMACH CANCER; TUMOR DIFFERENTIATION; ADENOCARCINOMA; AGED; BIOSYNTHESIS; IN SITU HYBRIDIZATION; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PERITONEUM TUMOR; SECONDARY; STOMACH TUMOR; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TRANSCRIPTOME;

EID: 84942101777     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0417-4     Document Type: Article

References (30)

1. Kamangar F, Dore GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.
2. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43:256–64.
3. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26:60–70.
4. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36.
5. Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013;31:1947–53.
6. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012;30:3570–7.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. ToGA Trial Investigators: trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
8. Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastrooesopageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer. 2012;15:313–22.
9. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–9.
10. Doi T, Koizumi W, Siena S, Cascinu S, Ohtsu M, Michael H, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol. 2003;22:258 (abs. 1036).
11. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. ACTS-GC Group: impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18:5992–6000.
12. Oh HS, Eom DW, Kang GH, Ahn YC, Lee SJ, Kim JH, et al. Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer. 2013;. doi:10.1007/S10120-013-0288-0.
13. Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer. 2004;90:2344–8.
14. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104:1372–6.
15. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18:2833–40.
16. Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16:84–93.
17. Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, et al. Lapatinib sensitivity of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Gastric Cancer. 2013;. doi:10.1007/S10120-013-0290-6.
18. Gao FF1, Dabbs DJ, Cooper KL, Bhargava R. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases. Am J Clin Pathol. 2014;141(1):102–10.
19. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.
20. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92:1331–46.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.
22. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1454–67.
23. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52:893–901.
24. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, et al. Up-regulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004;6:459–69.
25. Nakanishi H, Yasui K, Ikehara Y, Yokoyama H, Munesue S, Kodera Y, et al. Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis. Clin Exp Metastasis. 2005;22:137–47.
26. Yokoyama H, Ikehara Y, Kodera Y, Ikehara Y, Yatabe Y, Mochizuki Y, et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2 overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer. 2006;95:1504–13.
27. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, et al. The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res. 2011;17:3619–30.
28. Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe M, et al. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci. 2008;99:1471–8.
29. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2004;10:136–43.
30. Tajiri R, Ooi A, Fujimura T, Dobashi Y, Oyama T, Nakamura R, et al. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol. 2013;. doi:10.1016/j.humpath.2013.11.004.